Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

• the present invention relates to novel combinations of compounds, pharmaceutical compositions containing them, and their use in therapy.
• WO 95/21844, WO 95/29177, WO 96/02537 and WO 96/23783 disclose heterocyclic derivatives which are described as possessing 5HT2 receptor antagonist activity. These compounds are said to be of use in the treatment of various CNS disorders such as depression. D2-li e antagonists such as haloperidol, raclopride and sulpiride are known in the art, for example see Seeman et al., Current Opinion in Neurology and Neurosurgery, (1993), 6, 602 - 608.
• the present invention therefore provides a pharmaceutical composition for the treatment or prevention of CNS disorders which comprises:
• salts having 5HT2C or D2 activity can usually be isolated in salt form and the invention extends to compositions in which the compounds are in salt form.
• Preferred salts are pharmaceutically acceptable salts, for example acid addition salts such as hydrochlorides, hydrobromides, phosphates, acetates, fumarates, maleates, tartrates, citrates, oxalates, methanesulphonates and p-toluenesulphonates.
• the invention also extends to compositions in which the compounds are in stereoisomeric or tautomeric forms.
• Preferred 5HT2C antagonists include those disclosed in WO 92/05170, in particular the compound N-(l -methyl- lH-indol-5-yl)-N'-(3-pyridyl)urea (SB-200646).
• Another preferred compound is 5-methyl-l-(3-pyridylcarbamoyl)-2,3-dihydropyrrollo[2,3-f]indole (SB-206553) which is disclosed as Example 1 of WO 94/04533 and pharmaceutically acceptable salts thereof.
• a particularly preferred 5HT2C antagonist is 5-methyl- 6-trifluoromethyl-l-[6-(2-methylpyridin-3-yloxy)pyridin-3-ylcarbamoyl]indoline (SB- 243213) (which may also be called 2,3-dihydro-5-methyl-N-f2-(2-methyl-3- pyridinyl)oxy]-5-pyridinyl]-6-trifluoromethyl)-lH-indole-l-carboxamide) which is described as Example 1 in PCT/EP 97/03156.
• 5HT2C antagonists include those compounds disclosed in WO 93/18028, WO 94/04533, WO 94/18170, WO 94/22871, WO 95/21844, WO 95/29177, WO 96/02537, WO 96/23783.
• Preferred D2 antagonists include haloperidol, raclopride, sulpiride, ziprasidone, olanzapine, sertindole and quetiapine and pharmaceutically acceptable salts thereof.
• the compounds having 5HT2C and D2 antagonist activity can be administered together or individually for the treatment of CNS disorders, that is to say either concurrently or non-concurrently.
• Concurrent administration includes co- administration of separate dosage forms of the two agents or administration as a single dosage unit.
• Non-concurrently shall be taken to mean that the two agents are administered more than 24 hours apart.
• kits comprising in separate dosage forms a compound having 5HT2C antagonist activity and a compound having D2 antagonist activity.
• kits are of use in providing to patients when administration of separate doses of the two active ingredients is required.
• kits can also be provided where sequential administration of the 5HT2C antagonist and D2 antagonist is required.
• the invention also extends to pharmaceutical compositions comprising a compound having antagonist activity at both the 5HT2C and D2 receptors, that is to say a single compound having dual activity, and a pharmaceutically acceptable carrier for the treatment or prevention of CNS disorders such as schizophrenia.
• the invention therefore provides a compound having antagonist activity at both the 5HT2C and D2 receptors for use in the treatment of CNS disorders such as schizophrenia.
• compositions of the present invention are expected to be of use in the treatment of CNS disorders disclosed in the above mentioned patent applications such as schizophrenia, mood disorders, including depression, seasonal effective disorder and dysthymia; anxiety disorders, including generalised anxiety, panic disorder, agoraphobia, social phobia, obsessive compulsive disorder and post-traumatic stress disorder; memory disorders, including dementia, amnestic disorders and age-associated memory impairment; and disorders of eating behaviours, including anorexia nervosa and bulimia nervosa.
• Other CNS disorders include Parkinson's disease, dementia in Parkinson's disease, neuroleptic- induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders. Therefore in a further aspect the present invention provides a pharmaceutical composition which comprises a compound having 5HT2C antagonist activity, a compound having D2 antagonist activity, and a pharmaceutically acceptable carrier for use in therapy.
• the invention provides a pharmaceutical composition which comprises a compound having 5HT2C antagonist activity, a compound having D2 antagonist activity; and a pharmaceutically acceptable carrier in the manufacture of a medicament for the treatment of the aforementioned disorders.
• the invention provides a pharmaceutical composition which comprises a compound having 5HT2C antagonist activity, a compound having D2 antagonist activity; and a pharmaceutically acceptable carrier for use in the treatment or prophylaxis of depression.
• a pharmaceutical composition which comprises a compound having 5HT2C antagonist activity, a compound having D2 antagonist activity; and a pharmaceutically acceptable carrier for use in the treatment or prophylaxis of depression.
• compositions of the invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
• Compositions of the invention can also be administered in combination with other medicaments, for example conventional antidepressants or anxiolytics.
• a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
• Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
• the tablets may be coated according to methods well known in normal pharmaceutical practice.
• Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
• Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
• fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
• the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
• the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
• adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
• the composition can be frozen after filling into the vial and the water removed under vacuum.
• Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
• the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
• a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
• the composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
• the dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
• suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
• This compound can be prepared according to the procedure given in WO 92/05170.
• This compound can be prepared according to the procedure given in Example 1 of WO 94/04533.
• the hydrochloride can be prepared by treating a solution of the free base in methanol or propanol with concentrated hydrochloric acid.
• Activity is assessed by the reversal of haloperidol-induced catalepsy in the rat (bar method).
• a metal bar 10cm high x 10mm diameter is suspended between two upright posts, and the bar is divided into compartments with card or perspex partitions.
• Groups of rats are dosed intraperitoneally with a range of doses of the test compound or vehicle.
• the rats are positioned so that their hind legs contact the ground and their forelegs are draped over the horizontal bar.
• the measure of catalepsy is taken as the time taken for the rat to remove the front paws from the bar, with a maximum measurement of 120 seconds and the test is repeated at 30, 60 and 90 minutes.
• catalepsy rats are administered vehicle or haloperidol (3umol/kg ip) and tested for catalepsy at 30 and 60 minutes in the standard manner; the rats are then injected with a range of doses of the test compound and are tested for catalepsy 30 minutes later.
• SB-228357 significantly reversed haloperidol-induced catalepsy at doses of 0.32, 3.2 and 10 mg/kg po.
• SB-243213 significantly reversed haloperidol-induced catalepsy.
• the 5HT2B antagonist, SB-215505 0.1-3.2 mg/kg po
• the 5HT2A antagonist, MDL- 100907 did not reverse haloperidol-induced catalepsy.

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Psychiatry (AREA)
• Neurology (AREA)
• Organic Chemistry (AREA)
• Neurosurgery (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=10797573

Family Applications (1)

Country Status (19)

Families Citing this family (7)

Family Cites Families (1)

• 1996
  • 1996-07-26 GB GBGB9615767.2A patent/GB9615767D0/en active Pending
• 1997
  • 1997-07-22 HU HU9903619A patent/HUP9903619A3/hu unknown
  • 1997-07-22 BR BR9710568A patent/BR9710568A/pt not_active Application Discontinuation
  • 1997-07-22 KR KR1019997000622A patent/KR20000029564A/ko not_active Application Discontinuation
  • 1997-07-22 CZ CZ99237A patent/CZ23799A3/cs unknown
  • 1997-07-22 PL PL97331426A patent/PL331426A1/xx unknown
  • 1997-07-22 CN CN97197977A patent/CN1230894A/zh active Pending
  • 1997-07-22 WO PCT/EP1997/004159 patent/WO1998004289A2/en not_active Application Discontinuation
  • 1997-07-22 JP JP10508522A patent/JP2000516924A/ja active Pending
  • 1997-07-22 AU AU42972/97A patent/AU725817B2/en not_active Ceased
  • 1997-07-22 IL IL12821997A patent/IL128219A0/xx unknown
  • 1997-07-22 EP EP97918947A patent/EP0936924A2/en not_active Ceased
  • 1997-07-22 CA CA002261813A patent/CA2261813A1/en not_active Abandoned
  • 1997-07-22 NZ NZ333813A patent/NZ333813A/xx unknown
  • 1997-07-22 TR TR1999/00140T patent/TR199900140T2/xx unknown
  • 1997-07-24 ZA ZA976593A patent/ZA976593B/xx unknown
  • 1997-07-24 AR ARP970103348A patent/AR008083A1/es not_active Application Discontinuation
  • 1997-07-25 CO CO97042582A patent/CO5031292A1/es unknown
• 1999
  • 1999-01-25 NO NO990322A patent/NO990322L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events